338 related articles for article (PubMed ID: 29574128)
1. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Camorani S; Crescenzi E; Fedele M; Cerchia L
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide aptamers for glioma targeting: an update.
Camorani S; Cerchia L
Cent Nerv Syst Agents Med Chem; 2015; 15(2):126-37. PubMed ID: 25924917
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
5. Aptamer applications for targeted cancer therapy.
Barbas AS; Mi J; Clary BM; White RR
Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
[TBL] [Abstract][Full Text] [Related]
6. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.
Xiang D; Shigdar S; Qiao G; Wang T; Kouzani AZ; Zhou SF; Kong L; Li Y; Pu C; Duan W
Theranostics; 2015; 5(1):23-42. PubMed ID: 25553096
[TBL] [Abstract][Full Text] [Related]
7. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
Tolmachev V; Stone-Elander S; Orlova A
Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
[TBL] [Abstract][Full Text] [Related]
8. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
Ghosh S; Marrocco I; Yarden Y
Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic protein kinase inhibitors.
Grant SK
Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
[TBL] [Abstract][Full Text] [Related]
10. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
11. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
13. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of aptamers.
Kaur G; Roy I
Expert Opin Investig Drugs; 2008 Jan; 17(1):43-60. PubMed ID: 18095918
[TBL] [Abstract][Full Text] [Related]
15. Novel insights into the role of aptamers in the fight against cancer.
Maimaitiyiming Y; Hong F; Yang C; Naranmandura H
J Cancer Res Clin Oncol; 2019 Apr; 145(4):797-810. PubMed ID: 30830295
[TBL] [Abstract][Full Text] [Related]
16. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.
Kim M; Kim DM; Kim KS; Jung W; Kim DE
Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327
[TBL] [Abstract][Full Text] [Related]
17. Aptamers: new arrows to target dendritic cells.
Ganji A; Varasteh A; Sankian M
J Drug Target; 2016; 24(1):1-12. PubMed ID: 25950603
[TBL] [Abstract][Full Text] [Related]
18. Structural studies of full-length receptor tyrosine kinases and their implications for drug design.
Bajinting A; Ng HL
Adv Protein Chem Struct Biol; 2021; 124():311-336. PubMed ID: 33632469
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to drugs targeting receptor tyrosine kinases.
Rosenzweig SA
Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
